Literature DB >> 15306172

Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL.

Weerapan Khovidhunkit1, Philippe N Duchateau, Katalin F Medzihradszky, Arthur H Moser, Josefina Naya-Vigne, Judy K Shigenaga, John P Kane, Carl Grunfeld, Kenneth R Feingold.   

Abstract

BACKGROUND: Infection and inflammation are associated with atherosclerosis. During infection and inflammation, HDL decreases and there are changes in the levels of several HDL-associated proteins. To identify changes in the protein composition of HDL during infection and inflammation, a proteomic approach was utilized. METHODS AND
RESULTS: Using two-dimensional gel electrophoresis and mass spectrometry, we found the expected increases in apolipoprotein (apo) SAA and apo E, as well as a decrease in apo A-I on HDL isolated from mice injected with endotoxin. We identified apo A-IV and apo A-V as positive acute-phase proteins in mouse HDL. We also found an increase in hepatic mRNA levels of apo A-IV and apo A-V after injection of endotoxin. Interleukin-6 increased apo A-IV and apo A-V mRNA levels in Hep3B cells. Additionally, we demonstrated that the protein levels of apo A-II in acute-phase HDL and the hepatic mRNA levels of apo A-II were decreased.
CONCLUSIONS: Apo A-IV and A-V are positive acute-phase proteins that increase in the serum during inflammation while apo A-II is a negative acute-phase protein in mice. Similar to other positive and negative acute-phase proteins, changes in hepatic production account for the changes in serum levels. However, the changes in apo A-IV and apo A-V, two apolipoproteins whose activities are not fully understood, may serve functions other than regulating lipid metabolism during the acute-phase response (APR). Coupled with the other changes in HDL proteins that occur, these changes are likely to alter the functional properties of HDL perhaps increasing the risk of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306172     DOI: 10.1016/j.atherosclerosis.2004.04.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  Variable penetrance of metabolic phenotypes and development of high-fat diet-induced adiposity in NEIL1-deficient mice.

Authors:  Harini Sampath; Ayesha K Batra; Vladimir Vartanian; J Russ Carmical; Deborah Prusak; Irena B King; Brian Lowell; Lauriel F Earley; Thomas G Wood; Daniel L Marks; Amanda K McCullough; Lloyd R Stephen
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-02-01       Impact factor: 4.310

2.  Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.

Authors:  John S Millar; Katsunori Ikewaki; LeAnne T Bloedon; Megan L Wolfe; Philippe O Szapary; Daniel J Rader
Journal:  J Lipid Res       Date:  2010-10-22       Impact factor: 5.922

3.  Toll-like Receptor (TLR) Signaling Interacts with CREBH to Modulate High-density Lipoprotein (HDL) in Response to Bacterial Endotoxin.

Authors:  Aditya Dandekar; Yining Qiu; Hyunbae Kim; Jiemei Wang; Xia Hou; Xuebao Zhang; Ze Zheng; Roberto Mendez; Fu-Shin Yu; Ashok Kumar; Deyu Fang; Fei Sun; Kezhong Zhang
Journal:  J Biol Chem       Date:  2016-09-16       Impact factor: 5.157

Review 4.  Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.

Authors:  Jaroslav A Hubacek
Journal:  Gene       Date:  2016-08-02       Impact factor: 3.688

5.  Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.

Authors:  B Dorfmeister; S Brandlhofer; F G Schaap; M Hermann; C Fürnsinn; B P Hagerty; H Stangl; W Patsch; W Strobl
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

6.  Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications.

Authors:  Xuefeng B Ling; Jane L Park; Tanya Carroll; Khoa D Nguyen; Kenneth Lau; Claudia Macaubas; Edward Chen; Tzielan Lee; Christy Sandborg; Diana Milojevic; John T Kanegaye; Susanna Gao; Jane Burns; James Schilling; Elizabeth D Mellins
Journal:  Proteomics       Date:  2010-11-23       Impact factor: 3.984

7.  Combined statin and niacin therapy remodels the high-density lipoprotein proteome.

Authors:  Pattie S Green; Tomas Vaisar; Subramaniam Pennathur; J Jacob Kulstad; Andrew B Moore; Santica Marcovina; John Brunzell; Robert H Knopp; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Circulation       Date:  2008-09-02       Impact factor: 29.690

Review 8.  The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.

Authors:  Mahdi Garelnabi; Kenton Lor; Jun Jin; Fei Chai; Nalini Santanam
Journal:  Clin Biochem       Date:  2012-09-19       Impact factor: 3.281

Review 9.  Cardiovascular proteomics: past, present, and future.

Authors:  Melanie Y White; Jennifer E Van Eyk
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  Plasma apolipoprotein O level increased in the patients with acute coronary syndrome.

Authors:  Bi-lian Yu; Chen-lu Wu; Shui-ping Zhao
Journal:  J Lipid Res       Date:  2012-06-12       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.